Related Experiment Video
Updated: Jan 24, 2026

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure
Published on: February 8, 2022
Antithrombotic Therapy and Device-Related Thrombosis Following Endovascular Left Atrial Appendage Closure
Jacqueline Saw1, Jens Erik Nielsen-Kudsk2, Martin Bergmann3
1Division of Cardiology, Vancouver General Hospital, Vancouver, British Columbia, Canada.
Insights
Antithrombotic therapy after left atrial appendage closure (LAAC) is crucial for stroke prevention. Device-related thrombosis is a risk, necessitating careful management and surveillance post-LAAC.
Area of Science:
- Cardiology
- Medical Devices
- Thrombosis Research
Background:
- Left atrial appendage closure (LAAC) is a growing procedure for stroke prevention in nonvalvular atrial fibrillation patients.
- It is particularly important for individuals unable to tolerate or ineligible for oral anticoagulation.
- Understanding post-procedural management is key to optimizing outcomes.
Purpose of the Study:
- To review current evidence on antithrombotic therapy following LAAC.
- To assess the risk of device-related thrombosis (DRT) after LAAC.
- To discuss therapeutic options and rationale for antithrombotic strategies post-LAAC.
Main Methods:
- Systematic review of existing literature on antithrombotic therapy and DRT after LAAC.
- Analysis of current clinical practices and physician-dependent choices in antithrombotic regimens.
- Evaluation of patient-specific bleeding risk factors influencing therapeutic decisions.
Main Results:
- Device-related thrombosis is a significant complication of LAAC, with unclear etiology.
- Real-world data suggests dual-antiplatelet therapy or direct oral anticoagulation may be comparable to warfarin and aspirin for safety and DRT occurrence.
- Routine device imaging surveillance is recommended to detect DRT, which requires aggressive treatment due to high thromboembolic risks.
Conclusions:
- There are uncertainties and dilemmas regarding optimal antithrombotic therapy post-LAAC.
- The study provides an in-depth discussion on available options and the rationale for their use.
- Aggressive management of diagnosed DRT is essential to mitigate thromboembolic risks.
Objectives:
The aim of this study is to review the evidence on the use of antithrombotic therapy and risk of device-related thrombosis after left atrial appendage closure.
Background:
Left atrial appendage closure (LAAC) is increasingly performed for stroke prevention in patients with nonvalvular atrial fibrillation, especially those who cannot tolerate or are ineligible for oral anticoagulation.
Methods:
After device implantation for LAAC, different antithrombotic regimens with varying duration of therapy are currently used. Such selection depends on patients' risk for bleeding and physicians' choice.
Results:
Device-related thrombosis remains an Achilles' heel of LAAC, and the etiology remains incompletely understood. Dual-antiplatelet therapy, and direct oral anticoagulation may have similar safety and device-related thrombosis occurrence in real-world LAAC registries compared with warfarin and aspirin. Device imaging surveillance should be routinely performed to assess for device-related thrombosis, which if diagnosed should be treated aggressively, as it is associated with higher thromboembolic risks.
Conclusions:
Given the uncertainties and therapeutic dilemma, the authors provide an in-depth discussion of the options and rationale for antithrombotic therapy post-LAAC.
More Related Videos
Related Concept Videos
Surface Appendages of Archaea
Venous Thrombosis I: Introduction
Angle Closure Glaucoma: Treatment
Gene Therapy
Group Therapy
Venous Thrombosis III: Interprofessional Care

